# Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD

Study · id `cardio:ct-nct03593317` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03593317](<https://clinicaltrials.gov/study/NCT03593317>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03593317

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT03593317. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-20 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT03593317, source copy `cardio:ctgov-nct03593317-2026-02-09`, retrieved 2026-10-26)
- Started: 2024-12-20 (actual) (ClinicalTrials.gov record NCT03593317, source copy `cardio:ctgov-nct03593317-2026-02-09`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT03593317, source copy `cardio:ctgov-nct03593317-2026-02-09`, retrieved 2026-10-26)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT03593317, source copy `cardio:ctgov-nct03593317-2026-02-09`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT03593317, source copy `cardio:ctgov-nct03593317-2026-02-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03593317-2026-02-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
- Acronym: BRAVE
- Condition: Arrhythmogenic Right Ventricular Dysplasia
- Intervention (Drug): Spironolactone
- Intervention (Drug): Placebo
- Lead sponsor: Hospices Civils de Lyon
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Hospices Civils de Lyon (`cardio:org-hospices-civils-de-lyon`)

## Provenance

Content hash: 6ad1199ac2d00f4aefa7c61cb9ebdc8669137de60e0dc86d240fbd616b65cda0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
